Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 1

Status

Completed 2Unknown 1Terminated 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 31Carcinoma, Non-Small-Cell Lung 4Urinary Bladder Neoplasms 3Neoplasm Metastasis 3Colorectal Neoplasms 3Brain Neoplasms 3Stomach Neoplasms 2Salivary Gland Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Multiple Myeloma 2Lymphoma 2Lung Neoplasms 2Hematologic Neoplasms 2Wilms Tumor 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Solid Tumors 1Sarcoma, Synovial 1Rhabdomyosarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Pleuropulmonary blastoma 1Pathologic Complete Response 1Neurofibrosarcoma 1Neuroblastoma 1

Interventions

Carboplatin 361Pemetrexed 276Cisplatin 230Paclitaxel 213Docetaxel 205Gemcitabine 160Erlotinib Hydrochloride 150Bevacizumab 132pembrolizumab 129Radiotherapy 114Nivolumab 88durvalumab 84Drug Therapy 84osimertinib 82atezolizumab 58Vinorelbine 53Gefitinib 53Radiosurgery 50Cetuximab 39Taxes 37130-nm albumin-bound paclitaxel 36Ipilimumab 34anlotinib 33Surgical Procedures, Operative 33Magnetic Resonance Spectroscopy 33Etoposide 30Albumin-Bound Paclitaxel 29tislelizumab 27icotinib 27aflutinib 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Non-Small-Cell Lung × Ado-Trastuzumab Emtansine × Clear all
NCT02314481 2026-05-04

DARWINII

University College, London

Phase 2 Completed
50 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Genomic Instability

NCT04591431 2023-10-03

ROME

Fondazione per la Medicina Personalizzata

Phase 2 Unknown
400 enrolled
BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT03784599 2022-11-10

TRAEMOS

The Netherlands Cancer Institute

Phase 2 Terminated
28 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02289833 2019-08-07

A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Hoffmann-La Roche

Phase 2 Completed
49 enrolled 22 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡